Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Maravai Lifesciences Holdings' Net Cash Flow fell 62797.83% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$334.5 million, marking a year-over-year decrease of 2300338.4%. This contributed to the annual value of -$252.6 million for FY2024, which is 34172.9% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Net Cash Flow stood at -$26.3 million for Q3 2025, which was down 62797.83% from -$15.0 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Net Cash Flow's 5-year high stood at $172.9 million during Q3 2021, with a 5-year trough of -$255.8 million in Q4 2024.
  • Moreover, its 5-year median value for Net Cash Flow was -$571000.0 (2023), whereas its average is $396000.0.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Net Cash Flow skyrocketed by 155297.4% in 2021, and later plummeted by 540846.44% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Net Cash Flow (Quarter) stood at $3.5 million in 2021, then soared by 318.93% to $14.7 million in 2022, then plummeted by 131.6% to -$4.6 million in 2023, then plummeted by 5408.46% to -$255.8 million in 2024, then skyrocketed by 89.71% to -$26.3 million in 2025.
  • Its last three reported values are -$26.3 million in Q3 2025, -$15.0 million for Q2 2025, and -$37.4 million during Q1 2025.